Multicenter, randomized phase III trial to compare epirubicin and cyclophosphamide (EC) followed by docetaxel (T) to epirubicin and docetaxel (ET) followed by capecitabine (X) as adjuvant treatment for operable, node positive breast cancer patients
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Capecitabine (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin
- Indications Early breast cancer; HER2 negative breast cancer
- Focus Biomarker; Therapeutic Use
- 14 Dec 2019 Results (N= 15,457), a metanalysis of prospective randomized trials assessing efficacy of Capecitabine as a part of neo adjuvant or adjuvant therapy in patients with early breast cancer, presented at the 42nd Annual San Antonio Breast Cancer Symposium
- 04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
- 29 Oct 2005 New trial record.